Attendee Confcal 1 Welcome Box

Browsing Over 172 Presentations

Sort By Upcoming First

Biomarkers and translational research and precision medicine (ID 666)

5P - First clinical validation of the physical biomarker based on the nanomechanical tissue profiling in breast cancer for prediction of treatment outcome in a neoadjuvant therapy setting (ID 590)

6P - 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/ HER2-negative breast cancer (ID 450)

7P - An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer (ID 435)

8P - Mutational analysis of circulating tumor DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): results from the TREnd trial. (ID 286)

9P - BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumor BRCA1 mutation (ID 361)

10P - The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers (ID 593)

11P - A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence (ID 214)

12P - The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer (ID 575)

13P - Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC) (ID 365)

14P - Immunomodulatory effect of denosumab in early breast cancer: preliminary results of a randomized window-opportunity clinical trial D-Biomark (NCT03691311). (ID 384)

15P - The combined influence of receptor subtype, grade and TN status on breast cancer survival in recently treated women with non-metastatic disease in Norway (ID 432)